Health Condition 1: M179- Osteoarthritis of knee, unspecified
Conditions
Interventions
Intervention1: Habb-e- Mafasil,Roghan-e- Banafsha: Habb-e- Mafasil: 3 gm per day in two divided doses (2 pills of 750mg twice a day after meals)
Roghan-e- Banafsha:10-15 ml per day
Control Interventio
Sponsors
National Institute of Unani Medicine, Bengaluru
Eligibility
Inclusion criteria
Inclusion criteria: 1.Diagnosed cases of OA Knee Joint as per ACR Criteria16 (clinical, radiographical and laboratory). 2.Subjects of all genders aged 45-70 years. 3.Grade I and II of Kellgren Lawrence grading scale17
Exclusion criteria
Exclusion criteria: 1.Subjects who experience a rapid worsening of knee symptoms, have a hot swollen knee, have a previous knee replacement on the affected knee, have a history of significant trauma to the affected knee, have a joint injection or arthroscopy in the past 6 months, or have any major surgery in the last year. 2.Subjects currently taking, or in the past 3 months were taking, pain-relieving medications (e.g., nonsteroidal anti-inflammatory drugs, analgesics, and corticosteroids). 3.Subjects diagnosed with gout or pseudo gout within the last 3 months, have a history of gout in the knee joint, diagnosed with other inflammatory arthritis (e.g., rheumatoid arthritis, septic arthritis), and malignancy, diagnosed with a complex pain disorder or severe immobility (e.g., complex regional pain syndrome, severe back pain, multiple sclerosis, muscular dystrophy, Parkinson’s disease, or hemiplegia). 4.Participants with a recent diagnosis of, and/or currently suffering from uncontrolled medical conditions including but not limited to diabetes (RBS=180mg/dl), hypertension (=140/90mmHg), cardiovascular disease gall bladder disease/gallstones/biliary disease, endocrine disease, or malignancies. 5.Pregnant and lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in the total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC –Modified CRD Pune version)Timepoint: 0th day, 7th day, 14th day, 21th day, and 28th day | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Reduction in Pain intensity as per WOMAC (Modified CRD Pune version) pain scale 2)Reduction in stiffness as per WOMAC (Modified CRD Pune version) stiffness scale 3)Reduction in Restrictions of movements as per WOMAC (Modified CRD Pune version) physical activity scale Timepoint: 0th day, 7th day, 14th day, 21th day, & 28th day | — |
Countries
India
Contacts
Public ContactDr Mohd Riyazuddin
National Institute of Unani Medicine
Outcome results
None listed